Back to matchesWe found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitleTRAILBLAZER‐ALZ 4: Directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer's disease ‐ Results from 12‐months.AuthorsPain, Andrew; Ferguson, Margaret B; Wang, Hong; Salloway, Stephen; Lee, Elly; Papka, Michelle; Hu, Haoyan B; Lu, Ming; Oru, Ena B; Collins, Emily C.; Brooks, Dawn A.; Sims, John R.PublicationAlzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, Vol 19, p1ISSN1552-5260Publication typeArticleDOI10.1002/alz.082529